How Canada's Tilray is boosting the medical marijuana industry in Australia

By Admin
In an effort to provide groundbreaking research for a treatment of nausea and vomiting during chemotherapy, Canadian medical cannabis research and produ...

In an effort to provide groundbreaking research for a treatment of nausea and vomiting during chemotherapy, Canadian medical cannabis research and production company Tilray has teamed up with the NSW Government and the University of Sydney.

The partnership will create the largest clinical trial of marijuana’s affect on chemotherapy patients in the world. Tilray’s ultimate plan is to import cannabis products from its state-of-the-art Vancouver Island facility that has helped bring the global $250 billion industry to Australia.

RELATED TOPIC: Is marijuana the best remedy for PMS? Foria Relief says yes

“We are very excited and optimistic about this partnership with Tilray,” said University of Sydney associate professor Peter Grimison. “We believe Tilray is well positioned to develop appropriate medical products from cannabis.

“We envision additional future trials with products that they develop for other indications as well.”

RELATED TOPIC: Australian economy looks for lift from medical marijuana

It’s believed by many that the growing medicinal marijuana industry will create thousands of skilled jobs while generating millions of dollars in foreign investment.

The trial is scheduled to begin as early as this summer once regulatory approval and import permits are granted, and will be held at Chris O’Brien Lifehouse in Sydney as well as other sites in NSW. It will be conducted by an interdisciplinary group of researchers who specialise in cannabinoids and oncology.

RELATED TOPIC: Health Canada attacks marijuana advertising—Is the industry going up in smoke?

The purpose of the trial is to examine the safety and tolerability of a novel cannabis-derived study drug in patients undergoing chemotherapy.

“Tilray is at the forefront of clinical research in the medical cannabis field,” said Tilray director of clinical research Dr. Catherine Jacobson. “We are providing physicians and researchers with cannabis-derived study drugs that meet regulatory standards for human trials and which are based on studies indicating a high likelihood of success in treating specific diseases and disease-related symptoms.”

Let's connect!   

Click here to read the latest edition of Healthcare Global magazine!

Share

Featured Articles

UnitedHealth CEO Admits Hack hit Third of US Citizens' Data

UnitedHealth Group CEO Andrew Witty tells stunned US congressional hearing Change Healthcare cyberattack affects third of the US population

Why Sanofi Leads the way on Healthcare Sustainability

How French multinational Sanofi is ensuring delivery of essential medical supplies while being ESG-compliant

Philips Q1 Results hit by $1.1bn Respironics Settlement

As Royal Philips reports Q1 2024 results we profile the Netherlands-based healthcare technology company, who made the switch from consumer electronics

Vaccine Breakthrough on Antibiotics Resistant Diseases

Medical Devices & Pharma

Oracle Fusion Cloud Update Boost for Patients

Technology & AI

WHO Tightens air Quality Guidelines as Pollution Kills 7mn

Sustainability